The Sunshine Reporter

DelveInsight’s, “Type 2 Diabetes Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 2 Diabetes mellitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Type 2 Diabetes Pipeline Report

• DelveInsight’s Type 2 Diabetes Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Type 2 Diabetes treatment.
• The leading Type 2 Diabetes Pipeline includes such as Hanmi Pharmaceuticals, Sanofi, Eli Lily and Company, AstraZeneca, NovoNordisk,  Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG,  Adocia, Jiangsu Hengrui Medicine, Bristol Myers Squibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals,  Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others are developing potential drug candidates to improve the Type 2 Diabetes treatment scenario.
• The promising Type 2 Diabetes therapies in the pipeline includes such as Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801, saxagliptin, sitagliptin, Metformin, and others.
• LY3209590 “Basal insulin-Fc” is a large molecule comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is in Phase 2 stage of development for the treatment of Type2 diabetes.
• HM14220 is a combination of a long-acting insulin analog and a long-acting exendin-4 analog; Targeting once weekly administration. It is in the pre-clinical stage of development for the treatment of Type 2 Diabetes.

Get an overview of the pipeline landscape @ Type 2 Diabetes Pipeline Outlook

Type 2 Diabetes Overview

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes. Type 2 diabetes mellitus (T2DM) accounts for around 90% of all cases of diabetes. In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Type 2 diabetes primarily occurs as a result of obesity and lack of exercise. Some people are more genetically at risk than others. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to type 1 diabetes and gestational diabetes. Diagnosis of diabetes is by blood tests such as fasting plasma glucose, oral glucose tolerance test, or glycated hemoglobin (A1C). Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.

Latest Breakthroughs and Developments in the Type 2 Diabetes Treatment Landscape

• A significant step in developing new therapeutics for the treatment of Type 1 and Type 2 diabetes has been made by a world-first study conducted by Monash University in Melbourne, Australia.
• Beck and his colleagues compared continuous glucose monitoring to traditional finger-prick testing in Type 2 diabetics using insulin for a study that was published in the Journal of the American Medical Association in 2021. Continuous monitoring, they discovered, was linked to a noticeably higher decline in HbA1c. They also discovered that ongoing monitoring assisted individuals in avoiding dangerous and significant blood sugar dips (a.k.a. hypoglycemia). It is evident that utilising insulin has advantages for Type 2 diabetics, according to him.
• Sotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of heart failure and type 1 and type 2 diabetes. The scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type 1, or SGLT1, and sodium-glucose cotransporter type 2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.  SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is in the phase 3 stage of development to treat Type 2 diabetes mellitus.
• Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin brings with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.ORMD0801 is in the phase 3 stage of development to treat Type 2 diabetes mellitus.

Type 2 Diabetes Pipeline Insight Report

“Type 2 Diabetes Mellitus- Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type2 Diabetes Mellitus pipeline landscape is provided which includes the disease overview and Type 2 Diabetes Mellitus treatment guidelines. The assessment part of the report embraces, in depth Type2 Diabetes Mellitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 2 Diabetes Mellitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Type 2 Diabetes Emerging Drugs

• Sotagliflozin: Lexicon Pharmaceuticals
• ORMD0801: Oramed Pharmaceuticals
• LY3209590-Eli lily and Company
• HM12460A: Hanmi Pharmaceuticals
• HM14220: Hanmi Pharmaceuticals

Type 2 Diabetes Pipeline Therapeutics Analysis

There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.

For further information, refer to the detailed report @ Type 2 Diabetes Emerging Therapies

Scope of the Type 2 Diabetes Pipeline Report

• Coverage- Global
• Type 2 Diabetes Companies- Hanmi Pharmaceuticals, Sanofi, Eli Lily and Company, AstraZeneca, NovoNordisk,  Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG,  Adocia, Jiangsu Hengrui Medicine, Bristol Myers Squibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals,  Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others are developing potential drug candidates to improve the Type 2 Diabetes treatment scenario.
• Type 2 Diabetes Therapies- Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801, saxagliptin, sitagliptin, Metformin, and others
• Type 2 Diabetes Therapeutic Assessment by Product Type
• Type 2 Diabetes Therapeutic Assessment by Stage and Product Type
• Type 2 Diabetes Therapeutic Assessment by Route of Administration
• Type 2 Diabetes Therapeutic Assessment by Stage and Route of Administration
• Type 2 Diabetes Therapeutic Assessment by Molecule Type
• Type 2 Diabetes Therapeutic Assessment by Stage and Molecule Type
• Type 2 Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
• Type 2 Diabetes – Market Drivers and Barriers

Table of Content

1. Introduction
2. Executive Summary
3. Type 2 Diabetes mellitus: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Type 2 Diabetes mellitus – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotagliflozin: Lexicon Pharmaceuticals
9. Mid Stage Products (Phase II)
10. LY3209590: Eli lily and Company
11. Early Stage Products (Phase I)
12. HM12460A: Hanmi Pharmaceuticals
13. Preclinical and Discovery Stage Products
14. HM14220: Hanmi Pharmaceuticals
15. Inactive Products
16. Type 2 Diabetes mellitus- Key Companies
17. Type 2 Diabetes mellitus- Key Products
18. Type 2 Diabetes mellitus – Unmet Needs
19. Type 2 Diabetes mellitus – Market Drivers and Barriers
20. Type 2 Diabetes mellitus – Future Perspectives and Conclusion
21. Type 2 Diabetes mellitus Analyst Views
22. Type 2 Diabetes mellitus Key Companies
23. Appendix

Got Queries? Reach out for more information on the Type 2 Diabetes Pipeline Report- Type 2 Diabetes Clinical Trials

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/